Fexlamose (AER-01) is a thiol-modified carbohydrate agent with mucolytic property. Fexlamose cleaves disulfides to cause mucolysis. Fexlamose can be used for researchs of chronic obstructive pulmonary disease (COPD) and muco-obstructive lung diseases (MOLD) [1] [2].
In Vivo, Fexlamose (MUC-031) (131 mg/mL; intranasal instillation; three times in 1 day or twice a day for 2 weeks) decreases airway mucus plugging, lessens airway inflammation and improves survival in muco-obstructive lung disease (βENaC-Tg mice)[2].
References:
[1]. Vu SP, et al., Molecular Approaches to Treating Chronic Obstructive Pulmonary Disease: Current Perspectives and Future Directions. Int J Mol Sci. 2025 Feb 28;26(5):2184.
[2]. Addante A, et al. A. A novel thiol-saccharide mucolytic for the treatment of muco-obstructive lung diseases. Eur Respir J. 2023 May 25;61(5):2202022.
In Vivo, Fexlamose (MUC-031) (131 mg/mL; intranasal instillation; three times in 1 day or twice a day for 2 weeks) decreases airway mucus plugging, lessens airway inflammation and improves survival in muco-obstructive lung disease (βENaC-Tg mice)[2].
References:
[1]. Vu SP, et al., Molecular Approaches to Treating Chronic Obstructive Pulmonary Disease: Current Perspectives and Future Directions. Int J Mol Sci. 2025 Feb 28;26(5):2184.
[2]. Addante A, et al. A. A novel thiol-saccharide mucolytic for the treatment of muco-obstructive lung diseases. Eur Respir J. 2023 May 25;61(5):2202022.